Illumina is set to acquire SomaLogic from Standard BioTools in a deal valued at up to $425 million, including an upfront payment and performance-based milestones and royalties. SomaLogic’s SomaScan proteomics platform, which analyzes thousands of proteins using aptamer-based technology coupled with next-generation sequencing, complements Illumina’s multiomics and genomics capabilities. This acquisition is expected to accelerate biomarker discovery and disease profiling efforts by integrating SomaLogic's proteomics expertise into Illumina’s global platform. The deal underscores Illumina’s strategic commitment to advancing multi-dimensional biological insights for precision medicine applications.